MedTrace Logo

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

NCT02648204 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1201

Last updated 2019-10-15

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

semaglutide

Administered subcutaneously (s.c., under the skin) once-weekly.

DRUG

Dulaglutide

Administered subcutaneously (s.c., under the skin) once-weekly.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-06
Primary Completion
2017-04-10
Completion
2017-05-19

Countries

  • United States
  • Bulgaria
  • Croatia
  • Finland
  • Germany
  • Greece
  • Hong Kong
  • India
  • Ireland
  • Latvia
  • Lithuania
  • Portugal
  • Puerto Rico
  • Romania
  • Slovakia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02648204 on ClinicalTrials.gov